MARKET

HALO

HALO

Halozyme Thrp
NASDAQ
79.44
+2.52
+3.28%
After Hours: 79.00 -0.44 -0.55% 19:39 02/13 EST
OPEN
77.83
PREV CLOSE
76.92
HIGH
81.19
LOW
77.55
VOLUME
1.74M
TURNOVER
--
52 WEEK HIGH
82.22
52 WEEK LOW
47.50
MARKET CAP
9.34B
P/E (TTM)
16.70
1D
5D
1M
3M
1Y
5Y
1D
Is It Too Late To Consider Halozyme Therapeutics (HALO) After A 36% One Year Gain?
Simply Wall St · 15h ago
The top-performing pharma and biotech stocks as group sees resurgence
Seeking Alpha · 21h ago
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know
Barchart · 1d ago
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics
NASDAQ · 1d ago
Halozyme Biotech Acquisitions And M&A Plan Weigh On Valuation Case
Simply Wall St · 1d ago
Halozyme Therapeutics Inc. to Announce Financial and Operating Results
Reuters · 3d ago
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
PR Newswire · 3d ago
Why Halozyme Therapeutics (HALO) Is Up 8.1% After Raising 2026 Revenue Guidance to up to $1.81 Billion
Simply Wall St · 3d ago
More
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Webull offers Halozyme Therapeutics, Inc. stock information, including NASDAQ: HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.